BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mayer-Hamblett N, Kloster M, Ramsey BW, Narkewicz MR, Saiman L, Goss CH. Incidence and clinical significance of elevated liver function tests in cystic fibrosis clinical trials. Contemp Clin Trials 2013;34:232-8. [PMID: 23200843 DOI: 10.1016/j.cct.2012.11.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Guimbellot JS, Taylor-Cousar JL. Combination CFTR modulator therapy in children and adults with cystic fibrosis. Lancet Respir Med 2021;9:677-9. [PMID: 33965001 DOI: 10.1016/S2213-2600(21)00176-4] [Reference Citation Analysis]
2 Bodewes FA, van der Doef HP, Houwen RH, Verkade HJ. Increase of Serum γ-Glutamyltransferase Associated With Development of Cirrhotic Cystic Fibrosis Liver Disease. Journal of Pediatric Gastroenterology & Nutrition 2015;61:113-8. [DOI: 10.1097/mpg.0000000000000758] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
3 Vo HD, Xu J, Rabinowitz SS, Fisher SE, Schwarz SM. The Liver in Pediatric Gastrointestinal Disease. Journal of Pediatric Gastroenterology & Nutrition 2014;59:288-99. [DOI: 10.1097/mpg.0000000000000444] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Woodruff SA, Sontag MK, Accurso FJ, Sokol RJ, Narkewicz MR. Prevalence of elevated liver enzymes in children with cystic fibrosis diagnosed by newborn screen. Journal of Cystic Fibrosis 2017;16:139-45. [DOI: 10.1016/j.jcf.2016.08.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
5 Ronan NJ, Elborn JS, Plant BJ. Current and emerging comorbidities in cystic fibrosis. Presse Med 2017;46:e125-38. [PMID: 28554721 DOI: 10.1016/j.lpm.2017.05.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 6.4] [Reference Citation Analysis]
6 Cipolli M, Fethney J, Waters D, Zanolla L, Meneghelli I, Dutt S, Assael BM, Gaskin KJ. Occurrence, outcomes and predictors of portal hypertension in cystic fibrosis: A longitudinal prospective birth cohort study. Journal of Cystic Fibrosis 2020;19:455-9. [DOI: 10.1016/j.jcf.2019.09.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Leung DH, Narkewicz MR. Cystic Fibrosis-related cirrhosis. Journal of Cystic Fibrosis 2017;16:S50-61. [DOI: 10.1016/j.jcf.2017.07.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 5.6] [Reference Citation Analysis]
8 Debray D, Narkewicz MR, Bodewes FAJA, Colombo C, Housset C, de Jonge HR, Jonker JW, Kelly DA, Ling SC, Poynard T, Sogni P, Trauner M, Witters P, Baumann U, Wilschanski M, Verkade HJ. Cystic Fibrosis-related Liver Disease: Research Challenges and Future Perspectives. J Pediatr Gastroenterol Nutr. 2017;65:443-448. [PMID: 28753176 DOI: 10.1097/mpg.0000000000001676] [Cited by in Crossref: 49] [Cited by in F6Publishing: 18] [Article Influence: 12.3] [Reference Citation Analysis]
9 Pittman JE, Khan U, Laguna TA, Heltshe S, Goss CH, Sanders DB. Rates of adverse and serious adverse events in children with cystic fibrosis. J Cyst Fibros 2021:S1569-1993(21)00048-5. [PMID: 33745860 DOI: 10.1016/j.jcf.2021.02.013] [Reference Citation Analysis]